Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 93

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 93
---
 Shares
we are offering. An increase (decrease) of 100,000 in the number of Ordinary Shares offered by us would increase (decrease)
the net proceeds to us from this offering by $0.76 million, assuming no change in the assumed initial public offering price and
after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

We currently expect to use
the net proceeds from this offering for the following purposes:

| ● | approximately $4.5 million                                                                                                    
 for development activities (including the completion of our pivotal trial) and preparation of the PMA submission for GelrinC; |

| ● | approximately $1.0 million                                      
 for operations (manufacturing, regulatory affairs and patents); |

| ● | approximately $0.5 million               
 for research and development activities; |

| ● | approximately $0.5 million                                                          
 for EU marketing development (Medical Device Regulation qualification and scaleup); |

| ● | approximately $1.1 million for                                                                                                            
 the repayment of the Bridge Loan, the loans under the 2024 Loan Agreements, the 2025 Loan Agreements and the December 2024 Loan Agreement 
 and accrued interest and applicable risk premium;                                                                                         |

| ● | $0.25 million to be paid to the Chairman of our                                                                                  
 board of directors in consideration of his services to the Company since 2019, for which he has not received compensation, which 
 was approved by our shareholders on March 20, 2025;                                                                              |

| ● | $0.43 million for payment of the CSL Settlement (as defined 
 below); and                                                 |

| ● | the remainder for working capital and general corporate 
 purposes and possible future acquisitions.              |

Although we currently anticipate
that we will use the net proceeds from this offering as described above, there may be circumstances where a reallocation of funds is
necessary. Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate
with certainty the exact amounts of the net proceeds from this offering that may be used for any of the above purposes on a stand-alone
basis. Amounts and timing of our actual expenditures will depend upon a number of factors, including our sales, marketing and commercialization
efforts, regulatory approval and demand for our product candidates, operating costs and other factors described under “Risk Factors”
in this prospectus. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will
not have the opportunity